Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559655 | 0.86 | ADORA2A (0.44) | ADORA2AADORA3ADORA1GRIN2B | |
| SCHEMBL14393438 | 0.86 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL10456428 | 0.86 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL1244542 | 0.86 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL10458535 | 0.86 | ADORA2A (0.57) | ADORA2AADORA3ADORA1 | |
| SCHEMBL560123 | 0.85 | ADORA2A (0.53) | ADORA2AADORA3ADORA1CTSLSMYD2 | |
| SCHEMBL13612127 | 0.83 | ADORA2A (0.76) | ADORA2AADORA3ADORA1 | |
| SCHEMBL10455994 | 0.83 | ADORA2A (0.76) | ADORA2AADORA3ADORA1 | |
| SCHEMBL559613 | 0.82 | GRIN2B (0.42) | ADORA2AGRIN2BCSF1R | |
| SCHEMBL4565422 | 0.77 | GRIN2B (0.37) | ADORA2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516882-B | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS LLC | 2012-08-29 | — | — | CN | claimed |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | claimed |
| US-7985754-B2 | Selective antagonists of A2A adenosine receptors | TROVIS PHARMACEUTICALS, LLC (US) | 2011-07-26 | — | — | US | claimed |
| CN-101516882-A | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS LLC (US) | 2009-08-26 | — | — | CN | claimed |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2009-05-07 | — | — | US | claimed |
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-12-06 | — | — | US | disclosed |
| CN-101516882-B | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS LLC | 2012-08-29 | — | — | CN | disclosed |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2012-02-09 | — | — | US | disclosed |
| US-7985754-B2 | Selective antagonists of A2A adenosine receptors | TROVIS PHARMACEUTICALS, LLC (US) | 2011-07-26 | — | — | US | disclosed |
| CN-101516882-A | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS LLC (US) | 2009-08-26 | — | — | CN | disclosed |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2009-05-07 | — | — | US | disclosed |
| EP-2041136-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHealth, LLC (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008011007-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | PGXHEALTH, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309774-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20090118309-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
| US-20120035192-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.